Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms

Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Pharmiweb.com RSS Feed PharmiWeb Candidate Blog

Pharmiweb.com RSS Feed PharmiWeb Client Blog

Advertising

Press Releases

37 Press Releases
DateTitleCompany
03 Aug 15 Unichem Pharmaceuticals (USA), Inc. Issues a Voluntary Nationwide Recall of Hydrochlorothiazide Tablets Due to the Potential Presence of Foreign Tablets Bayer HealthCare,
Published by
PharmiWeb.com
03 Aug 15 Finacea(R) (azelaic acid) Foam 15%, Approved by U.S. FDA for Topical Treatment of the Inflammatory Papules and Pustules of Mild to Moderate Rosacea Bayer HealthCare,
Published by
PharmiWeb.com
16 Jul 15 For Families Impacted by Cancer, "Pillow Talk" Program May Help with Hard Conversations Bayer HealthCare,
Published by
PR Newswire
08 Jun 15 Afaxys and Bayer HealthCare Form Alliance to Expand Access to Contraception in the Public Health Sector Bayer HealthCare Pharmaceuticals, Inc.,
Published by
PR Newswire
17 Apr 15 World Hemophilia Day: April 17 2015: Bayer Joins Leading International Organizations to Empower Future Leaders in Hemophilia Hematology and Thrombosis Bayer HealthCare,
Published by
PR Newswire
24 Mar 15 Bayer Furthers Global Efforts to Lead Fight Against Vector-Borne Diseases Bayer HealthCare
03 Feb 15 Study shows Mirena® (LNG-IUS 52mg) significantly more effective than copper IUD in preventing pregnancy Bayer HealthCare
27 Jan 15 Bayer Forms Collaboration with Academic and Governmental Institutions for Global Phase III study to evaluate Xarelto®? (rivaroxaban) in patients with a recent Embolic Stroke of Undetermined Source Bayer HealthCare,
Published by
PharmiWeb.com
10 Sep 14 Safety and Sustained Benefits of Adempas® From Bayer Confirmed by Results of Long-Term Studies Bayer HealthCare
02 Sep 14 Once-daily Xarelto® indicates benefit in the first trial to evaluate prospective use in atrial fibrillation (AF) patients undergoing cardioversion1 Bayer HealthCare,
Published by
PharmiWeb.com
14 Aug 14 SURVEY SHOWS MANY UK WOMEN ARE NOT CLUED-UP WHEN IT COMES TO CONTRACEPTION Bayer HealthCare
07 May 14 Survey shows less than 5% of GPs prescribe in line with NICE guidelines on Heavy Menstrual Bleeding (HMB) Bayer HealthCare,
Published by
Porter Novelli
01 Apr 14 Launch of new long-acting contraceptive Jaydess®?(Levonorgestrel Intrauterine System (LNG IUS) 13.5mg) offers women contraceptive protection for up to three years Bayer HealthCare
25 Sep 13 Bayer Senior Executive to Lead World Self-Medication Industry: Global Self-Medication Industry Association Elects Bayer HealthCare’s Erica Mann as Incoming Chair Bayer HealthCare,
Published by
Business Wire
03 Jun 13 Positive Phase III Data on Sorafenib Show Significant Improvement in Progression-Free Survival Time in Patients with Radioactive Iodine Refractory Differentiated Thyroid Cancer Bayer HealthCare Pharmaceuticals,
Published by
Pharmiweb.com
29 May 13 Antitrust clearance obtained for Bayer's acquisition of Conceptus BAYER HEALTHCARE LLC,
Published by
PR Newswire
11 Feb 13 Bayer Submits New Drug Application for Riociguat for the Treatment of Pulmonary Arterial Hypertension and Persistent/Recurrent Chronic Thromboembolic Pulmonary Hypertension BAYER HEALTHCARE LLC,
Published by
PR Newswire
08 Jun 12 Bayer Partnership Delivers Industry-First Dose Management Offering BAYER HEALTHCARE,
Published by
PR Newswire
23 May 12 Bayer Submits New Drug Application for Regorafenib for the Treatment of Metastatic Colorectal Cancer BAYER HEALTHCARE LLC,
Published by
PR Newswire
17 Apr 12 Real-World Experience Reaffirms Bayer’s Xarelto® (Rivaroxaban) as Effective in Protecting Patients Against Venous Blood Clots Bayer HealthCare
13 Apr 12 Bayer’s Xarelto® (Rivaroxaban) Submitted for EU Marketing Authorisation for the Treatment of Pulmonary Embolism (PE) and Prevention of Recurrent Deep Vein Thrombosis (DVT) and PE in adults Bayer HealthCare
30 Mar 12 Bayer’s Xarelto® (rivaroxaban) Gains NICE Recommendation for Stroke Prevention in Patients with Non-Valvular Atrial Fibrillation Bayer HealthCare
28 Feb 12 Bayer’s Xarelto® (rivaroxaban) Granted Priority Review by US FDA to Prevent Secondary Cardiovascular Events in Patients with ACS Bayer HealthCare
21 Dec 11 Bayer’s Xarelto® (rivaroxaban) is now Approved in the UK for Prevention of non-valvular AF-related Stroke and Systemic Embolism and Treatment of DVT Bayer HealthCare
11 Nov 11 Bayer Virtual Walk for Hemophilia Raises Awareness and Funds for People With Bleeding Disorders BAYER HEALTHCARE LLC,
Published by
PR Newswire
16 Aug 11 Bayer Healthcare named in advertisements for breaches of the ABPI Code of Practice Bayer Healthcare,
Published by
PharmiWeb.com
11 Aug 11 New England Journal of Medicine Publishes Results of Landmark ROCKET AF Study of Bayer’s Xarelto® (rivaroxaban) Bayer Healthcare,
Published by
Fleishman-Hillard
08 Apr 11 Bayer and Regeneron Announce Start of Phase 3 Clinical Program in Diabetic Macular Edema Bayer HealthCare,
Published by
PharmiWeb.com
15 Mar 11 TV Personality Vanessa Minnillo Teams Up With Bayer and March of Dimes to Launch National Folate Awareness Campaign BAYER HEALTHCARE LLC,
Published by
PR Newswire
07 Jan 11 Bayer’s Rivaroxaban Submitted for EU Marketing Authorisation in Stroke Prevention in Patients with Non-Valvular Atrial Fibrillation Bayer HealthCare,
Published by
PharmiWeb.com
Advertising
Share | | |
Site Map | Privacy & Security | Cookies | Terms and Conditions

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.